Katharina Kuba1, Peter Esser1, Angela Scherwath2, Lena Schirmer2, Frank Schulz-Kindermann2, Andreas Dinkel3, Friedrich Balck4, Uwe Koch2, Nicolaus Kröger5, Heide Götze1, Anja Mehnert1,2. 1. Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany. 2. Department and Outpatient Clinic of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. 4. Department of Medical Psychology and Medical Sociology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. 5. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
BACKGROUND: In this prospective multicenter study, we investigated cancer-and-treatment-specific distress (CTXD) and its impact on symptoms of posttraumatic stress disorder (PTSD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: Patients were consulted before (T0, N = 239), 3 (T1, N = 150), and 12 months (T2, N = 102) after HSCT. Medical (eg, diagnosis and pretreatment) and demographic information, CTXD and PTSD (PCL-C) were assessed. RESULTS: Random intercept models revealed that the sum score of CTXD was highest pre-HSCT (T0), decreased by T1 (γ = -.18, 95% CI [-.26/-.09]), and by T2 (γ = -.10, 95% CI [-.20/-.00]). Uncertainty, family strain, and health burden were rated most distressing during HSCT. Uncertainty and family strain decreased from T0 to T1 (γ = -.30, 95% CI [-.42/-.17]; γ = -.10, 95% CI [-.20/-.00]) and health burden from T1 to T2 (γ = -.21, 95% CI [-.36/.05]). Women were more likely to report uncertainty (γ = .38, 95% CI [.19/.58]), family strain (γ = .38, 95% CI [.19/.58]), and concerns regarding appearance and sexuality (γ = .31, 95% CI [.14/.47]) than men. Uncertainty (γ = .18, 95% CI [.12/.24]), appearance and sexuality (γ = .09, 95% CI [.01/.16]), and health burden (γ = .21, 95% CI [.14/.27]) emerged as predictors of PTSD symptomatology across the 3 assessment points. CONCLUSIONS: Our data provide first evidence regarding the course of 6 dimensions of CTXD during HSCT and their impact on PTSD symptomatology. Specifically, results emphasize the major burden of uncertainty pre-HSCT and the impact of uncertainty and concerns regarding appearance and sexuality on PTSD symptomatology.
BACKGROUND: In this prospective multicenter study, we investigated cancer-and-treatment-specific distress (CTXD) and its impact on symptoms of posttraumatic stress disorder (PTSD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). METHODS:Patients were consulted before (T0, N = 239), 3 (T1, N = 150), and 12 months (T2, N = 102) after HSCT. Medical (eg, diagnosis and pretreatment) and demographic information, CTXD and PTSD (PCL-C) were assessed. RESULTS: Random intercept models revealed that the sum score of CTXD was highest pre-HSCT (T0), decreased by T1 (γ = -.18, 95% CI [-.26/-.09]), and by T2 (γ = -.10, 95% CI [-.20/-.00]). Uncertainty, family strain, and health burden were rated most distressing during HSCT. Uncertainty and family strain decreased from T0 to T1 (γ = -.30, 95% CI [-.42/-.17]; γ = -.10, 95% CI [-.20/-.00]) and health burden from T1 to T2 (γ = -.21, 95% CI [-.36/.05]). Women were more likely to report uncertainty (γ = .38, 95% CI [.19/.58]), family strain (γ = .38, 95% CI [.19/.58]), and concerns regarding appearance and sexuality (γ = .31, 95% CI [.14/.47]) than men. Uncertainty (γ = .18, 95% CI [.12/.24]), appearance and sexuality (γ = .09, 95% CI [.01/.16]), and health burden (γ = .21, 95% CI [.14/.27]) emerged as predictors of PTSD symptomatology across the 3 assessment points. CONCLUSIONS: Our data provide first evidence regarding the course of 6 dimensions of CTXD during HSCT and their impact on PTSD symptomatology. Specifically, results emphasize the major burden of uncertainty pre-HSCT and the impact of uncertainty and concerns regarding appearance and sexuality on PTSD symptomatology.
Authors: Claire J Han; Biljana Gigic; Martin Schneider; Yakup Kulu; Anita R Peoples; Jennifer Ose; Torsten Kölsch; Paul B Jacobsen; Graham A Colditz; Jane C Figueiredo; William M Grady; Christopher I Li; David Shibata; Erin M Siegel; Adetunji T Toriola; Alexis B Ulrich; Karen L Syrjala; Cornelia M Ulrich Journal: J Cancer Surviv Date: 2020-03-12 Impact factor: 4.442
Authors: Jessica Liang; Stephanie J Lee; Barry E Storer; Bronwen E Shaw; Eric J Chow; Mary E Flowers; Elizabeth F Krakow; Merav Bar; Karen L Syrjala; Rachel B Salit; Chareeni E Kurukulasuriya; Heather S L Jim Journal: Biol Blood Marrow Transplant Date: 2018-08-09 Impact factor: 5.742
Authors: Daniel R Richardson; Ying Huang; Heather L McGinty; Patrick Elder; Joanna Newlin; Cyndi Kirkendall; Leslie Andritsos; Don Benson; William Blum; Yvonne Efebera; Sam Penza; Craig Hofmeister; Samantha Jaglowski; Rebecca Klisovic; Sumithira Vasu; Basem William; Steven Devine; Ashley E Rosko Journal: Bone Marrow Transplant Date: 2018-02-14 Impact factor: 5.483
Authors: Mohamad S Alabdaljabar; Ibrahim N Muhsen; Jennifer M Knight; Karen L Syrjala; Shahrukh K Hashmi Journal: Blood Rev Date: 2020-12-01 Impact factor: 8.250
Authors: Ryan D Nipp; Areej El-Jawahri; Sara M D'Arpino; Andy Chan; Charn-Xin Fuh; P Connor Johnson; Daniel E Lage; Risa L Wong; William F Pirl; Lara Traeger; Barbara J Cashavelly; Vicki A Jackson; David P Ryan; Ephraim P Hochberg; Jennifer S Temel; Joseph A Greer Journal: Cancer Date: 2018-06-15 Impact factor: 6.860
Authors: Steffen T Simon; Anne Pralong; Michael Hallek; Christoph Scheid; Udo Holtick; Marco Herling Journal: Ann Hematol Date: 2021-05-06 Impact factor: 3.673
Authors: Annika M Kisch; Karin Bergkvist; Anette Alvariza; Kristofer Årestedt; Jeanette Winterling Journal: Support Care Cancer Date: 2020-10-30 Impact factor: 3.603